Book your demo

Want to know how Resilience Care can support your teams and projects? Contact us !

Category

Oncology
Testimonials

Written by

Summary

Title

Pioneering Early Phase Trials: PROs and Dose Optimization

Expert Prof. Christophe Massard explains that phase I oncology trials must now integrate dose optimization, toxicity assessment with structured PROs to inform the optimal dose for later phases. Discover the key role of RPM and digital tools in this process.

Dec 4, 2025

3 minutes

Watch Prof. Christophe Massard, Medical Oncologist and Head of DITEP at Gustave Roussy, discuss the crucial evolution of early-phase oncology trials. He explains why defining safety requires dose optimization, integrating acute/chronic toxicity assessment with Patient-Reported Outcomes (PROs). Learn how Remote Patient Monitoring (RPM) and digital tools capture high-frequency, structured data to accelerate this path from Phase I to drug approval.

Heading

Pioneering Early Phase Trials: PROs and Dose Optimization

Expert Prof. Christophe Massard explains that phase I oncology trials must now integrate dose optimization, toxicity assessment with structured PROs to inform the optimal dose for later phases. Discover the key role of RPM and digital tools in this process.

Dec 4, 2025

3 minutes

Watch Prof. Christophe Massard, Medical Oncologist and Head of DITEP at Gustave Roussy, discuss the crucial evolution of early-phase oncology trials. He explains why defining safety requires dose optimization, integrating acute/chronic toxicity assessment with Patient-Reported Outcomes (PROs). Learn how Remote Patient Monitoring (RPM) and digital tools capture high-frequency, structured data to accelerate this path from Phase I to drug approval.

Pioneering Early Phase Trials: PROs and Dose Optimization

Expert Prof. Christophe Massard explains that phase I oncology trials must now integrate dose optimization, toxicity assessment with structured PROs to inform the optimal dose for later phases. Discover the key role of RPM and digital tools in this process.

Dec 4, 2025

3 minutes

Watch Prof. Christophe Massard, Medical Oncologist and Head of DITEP at Gustave Roussy, discuss the crucial evolution of early-phase oncology trials. He explains why defining safety requires dose optimization, integrating acute/chronic toxicity assessment with Patient-Reported Outcomes (PROs). Learn how Remote Patient Monitoring (RPM) and digital tools capture high-frequency, structured data to accelerate this path from Phase I to drug approval.

Pioneering Early Phase Trials: PROs and Dose Optimization

Expert Prof. Christophe Massard explains that phase I oncology trials must now integrate dose optimization, toxicity assessment with structured PROs to inform the optimal dose for later phases. Discover the key role of RPM and digital tools in this process.

Dec 4, 2025

3 minutes

Watch Prof. Christophe Massard, Medical Oncologist and Head of DITEP at Gustave Roussy, discuss the crucial evolution of early-phase oncology trials. He explains why defining safety requires dose optimization, integrating acute/chronic toxicity assessment with Patient-Reported Outcomes (PROs). Learn how Remote Patient Monitoring (RPM) and digital tools capture high-frequency, structured data to accelerate this path from Phase I to drug approval.

Pioneering Early Phase Trials: PROs and Dose Optimization

Expert Prof. Christophe Massard explains that phase I oncology trials must now integrate dose optimization, toxicity assessment with structured PROs to inform the optimal dose for later phases. Discover the key role of RPM and digital tools in this process.

Dec 4, 2025

3 minutes

Watch Prof. Christophe Massard, Medical Oncologist and Head of DITEP at Gustave Roussy, discuss the crucial evolution of early-phase oncology trials. He explains why defining safety requires dose optimization, integrating acute/chronic toxicity assessment with Patient-Reported Outcomes (PROs). Learn how Remote Patient Monitoring (RPM) and digital tools capture high-frequency, structured data to accelerate this path from Phase I to drug approval.

Speakers:

Prof. Christophe Massard EN
Medical Oncologist — Head of the DITEP at Gustave Roussy — University Professor at Paris Saclay
Gustave Roussy

Related articles

Oncology
Testimonials

Pioneering Early Phase Trials: PROs and Dose Optimization

Dec 4, 2025

3 minutes

Oncology
Online Conferences

Resilience Conference: Patient Reported Outcomes in Research and the revolution of AI

Dec 4, 2025

15 minutes

Oncology
Testimonials

Improving Cancer Care: The Power of Remote Patient Monitoring (RPM)

Dec 4, 2025

2 minutes

Ready to Implement 
Resilience in your Facility ?

Let’s discuss how our solutions can help you unlock the full potential of your data and improve patient outcomes.